PL EN


2012 | 3 | 482-488
Article title

Współczesne możliwości leczenia chorób obturacyjnych

Authors
Content
Title variants
Languages of publication
PL
Abstracts
Keywords
PL
astma   POChP  
Contributors
References
  • The ENFUMOSA corss-sectional European multicentre study of the clinical phenotype of chronic severe asthma.European Network of Understanding Mechanisms of Severe Asthma. Eur Respir J 2003; 22: 470−477.
  • Moore WC, Bleecker ER, Curran-Everett D, et al. Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute’s Severe Asthma Research Program. J Allergy Clin Immunol 2007; 119: 405−413.
  • Moffatt MF, Kabesch M, Liang L, et al. Genetic variants regulating ORMDL3 expression contribute to the risk of childhood asthma. Nature 2007; 448: 470–473.
  • Baterman ED, Boushery HA, Bousquet J, et al. Can guideline-defined asthma control be achived? The Gaining Optomal Asthma Control study. Am J Respir Crt Care Med 2004; 170: 836−844.
  • Masoli M, Fabian D, Holt S, et al. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 2004; 59: 469−478.
  • Adcock IM, Chung KF, Caramori G, et al. Kinase inhibitors and airway inflammation. Eur J Pharmacol 2006; 53:118−132.
  • Sturton RG, Nicholson AG, Trifilieff A, et al. Pharmacological characterization of indacaterol, a novel once-daily inhaled β2-adrenoreceptor agonist, on small airways in human and rat precision-cut lung slices. J Pharmacol Exp Ther 2008; 324: 270−275.
  • Cazzola M, Matera MG. Novel long-acting bronchodilators for COPD and asthma. Br J Pharmacol 2008; 155(3):291−299.
  • Brown AD, Bunnage ME, Glossop P, et al. The discovery of long acting β2-adrenoreceptor agonists. Bioorg Med Chem Lett 2007; 17: 4012–4015.
  • Battram C, Charlton SJ, Cuenoud B, et al. In vitro and in vivo pharmacological characterization of 5-[(R)-2-(5,6-diethylindan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one (indacaterol), a novel inhaled β2 adrenoceptor agonist with a 24-h duration of action. J Pharmacol Exp Ther 2006; 317: 762–770.
  • Barnes PJ, Stockley RA. COPD: current therapeutic interventions and future approaches. Eur Respir J 2005; 25:1084−1106.
  • Vestbo J, Vogelmeier C, Creemers J, et al. Onset of effect of Aclidinium, a novel, long-acting muscarinic antagonist, in patients with COPD. COPD 2010; 7(5): 331−336.
  • Hansel TT, Neighbour H, Erin EM, et al. Glycopyrrolate causes prolonged bronchoprotection and bronchodilatation in patients with asthma. Chest 2005; 128: 1974−1979.
  • Płusa T. Nowe leki kontrolujące obturację dróg oddechowych u chorych na POChP. Pol Merk Lek 2011; 30(175): 5−9.
  • Schelfhout V, Joos G, Garcia Gil E, et al. Bronchodilator/bronchoprotective effects of aclidinium bromide, a novel long-acting anticholinergic: a phase I study. Eur Respir J 2007; 30: 356.
  • Płusa T. Rationale basis for new anticholinergic drugs for chronic obstructive pulmonary disease. Int Rev Allergol Clin Immunol 2011; 17(3−4): 49−52.
  • Lu S, Parekh DD, Kuznetsova O, et al. An oral selective M3 anticholinergic receptor antagonist in COPD. Eur Respir J 2006; 28: 772–780.
  • Patacchini R, Bergamaschi M, Harrison S, et al. In vitro pharmacological profile of CHF 5407, a potent, long-acting and selective muscarinic M3 receptor antagonist. Eur Respir J 2007; 30: 25.
  • Villetti G, Bassani F, Bergamaschi M, et al. In vivo potent and long-lasting bronchodilator activity of muscarinic M3 receptor antagonist CHF5407. Eur Respir J 2007; 30: 26.
  • Barnes PJ. New therapies for asthma. Trends Mol Med, 2006; 12: 515−520.
  • Bateman ED, Hurd SS, Barnes PJ, et al. Global strategy for asthma management and prevention: GINA executive summary.Eur Respir J 2008; 31: 143–178.
  • Arievich H, Potena A, Fonay K, et al. Formoterol given either alone or together with tiotropium, reduces the rate of exacerbations in stable COPD patients. Eur Respir J 2006; 28: 430.
  • Fitzgerald MF, Spicer D, Ma JY, et al. Efficacy of the p38 MAP kinase inhibitor, SD-282, in an inflammatory model of COPD in A/J mice. Proc Am Thorac Soc 2006; 3: A850.
  • Rabe KF, Timmer W, Sagkriotis A, Viel K. Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD. Chest 2008; 134(2): 255−262.
  • Joos G, Schelfhout V, Kanniess F, et al. Bronchodilator effects of aclidinium bromide, a novel long-acting anticholinergic,in COPD patients: a phase II study. Eur Respir J 2007; 30: 210.
  • Paul-Clark MJ, Roviezzo F, Flower RJ, et al. Glucocorticoid receptor nitration leads to enhanced anti-inflammatory effects of novel steroid ligand. J Immunol 2003; 171: 3245−3252.
  • Peters-Golden M, Henderson WR. Leukotrienes. N Engl J Med 2007; 357: 1841−1854.
  • Pettipher R, Hansel TT, Armer R. Antagonism of the prostaglandin D2 receptors and CRTH2 as an approach to treat allergic diseases. Nat Rev Drug Discov 2007; 6: 313−325.
  • Lever R, Page CP. Novel drug development opportunities for heparin. Nat Rev Drug Discov 2002; 1: 140−148.
  • Kips JC, O’Connor BJ, Laugley SJ, et al. Effect of SCH55700 a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. Am J Respir Crit Care Med 2003; 167: 1655−1659.
  • Rothenberg ME, Klion AD, Roufosse FE, et al. Treatment of patients with the hypereosinophilic syndrome with mepolizumab.N Engl J Med 2008; 358: 1215−1228.
  • Borish LC, Nelson HS, Corren J, et al. Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J Allergy Clin Immunol 2001; 107: 963−970.
  • Caramori G, Groneberg D, Ito K, et al. New drugs targeting Th2 lymphocytes in asthma. J Occup Med Toxicol 2008;3: 56.
  • Wenzel SE, Balzar S, Ampleford E, et al. IL4R alpha mutations are associated with asthma exacerbations and mast cell/IgE expression. Am J Respir Crit Care Med 2007; 175: 570−576.
  • Bryan SA, O’Connor BJ, Matti S, et al. Effects of recombinant human interleukin-12 on eosinophils, airway hyperresponsiveness,and the late asthmatic response. Lancet 2000; 356: 2149−2153.
  • Berry MA, Hargadon B, Shelley M, et al. Evidence of a role of tumor necrosis factor alpha in refractory asthma. N Engl J Med 2006; 354: 697−708.
  • Ravensberg AJ, Luijk B, Westers P, et al. The effect of a single inhaled dose of a VLA-4 antagonist on allergen-induced airway responses and airway inflammation in patients with asthma. Allergy 2006; 61: 1097−1103.
  • Roth SY, Denu JM, Allis CD. Histone acetyltransferases. Annu Rev Biochem 2001; 70: 81−120.
  • Barnes PJ. Corticosteroid effects on cell signaling. Eur Respir J 2006; 27: 413−426.
  • Poole JA, Meng J, Reff M, et al. Anti-CD23 monoclonal antibody, lumiliximab, inhibited allergen-induced responses in antigen-presenting cells and T cells from atopic subjects. J Allergy Clin Immunol 2005; 116: 780−788
  • Idzko M, Hammad H, van Nimwegen M, et al. Local application of FTY720 to the lung abrogates experimental asthma by altering denritic cell function. J Clin Invest 2006; 116: 2935−2944.
  • Simpson JL, Powell H, Boyle MJ, et al. Clarithromycin targets neutrophilic airway inflammation in refractory asthma.Am J Respir Crit Care Med 2008; 177: 148−155.
  • Chung KF, Fan CK. Phosphidiesterase inhibitors in airways disease. Eur J Pharmacol 2006; 533: 110−117.
  • Eynott PR, Nath P, Leung SY, et al. Allergen-induced inflammation and airway epithelial and smooth muscle cell proliferation:role of Jun N-terminal kinase. Br J Pharmacol 2003; 140: 1373−1380
  • Yamamoto N, Takeshita K, Shichijo M, et al. The orally available spleen tyrosine kinase 2[7-(3,4-dimethoxyphenyl)-imidazol[1,2-c]pyrimidin-5ylamino]nicotiamide dihydrochloride (BAY 61-3606) blocks antigen-induced airway inflammation
  • Quarcoo D, Weixler S, Groneberg D, et al. Inhibition of signal trnsducer and activator of transcription and hyperreactivity.J Allergy Clin Immunol 2004; 114: 288−295.
  • Kirkham P, Ruhman I. Oxidative stress in asthma and COPD: antioxidants as a therapeutic strategy. Pharmacol Ther 2006; 111: 476−494.
  • Xystrakis E, Kusumakar S, Boswell S, et al. Reversing the defective induction of IL-10-secreting regulatory T cells in glucucorticosteroid-resistant asthma patients. J Clin Invest 2006; 116: 146−155
Document Type
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.desklight-c888a594-a866-4ea7-8a38-3593fbee39a1
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.